The PI3-kinase (PI3K)/mTOR pathway is aberrantly activated up to 60% of clinical breast cancers, facilitating tumor cell growth, survival, metabolism, and invasion [42, 43]. This evidence concerns the gene MTOR and breast carcinoma.